Surprisingly, GFAP is also described as a potential biomarker for early AD in the saliva of MCI and AD patients where its levels are correlated with Aβ42, IL-1β, and caspase-8 (Katsipis et al., 2021). This evidence concerns the gene CASP8 and Alzheimer disease.